Figures computed from official regulatory filings — .
Analysttarget 15.5 USD (+276%) · consensus 3.67/5 · 1 buy · 2 hold · 0 sell
Ownershipinsiders 7.71% · institutions 46.43% · short 3.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Passage BIO, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
44 buys43 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lynx1 Capital Management LPtrack record | Buy | $206.1K | conv 34 |
| Kapadia Sandip | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Countouriotis Athenatrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Porter Derrell | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kassberg Thomas Richard | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOWEN MAXINEtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sondhi Dolan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chou William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borthwick Kathleen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borthwick Kathleen | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chou William | Sell | $75.2K | SEC |
| Chou William | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borthwick Kathleen | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borthwick Kathleen | Sell | $38K | Unusual size | SEC |
| Chou William | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Borthwick Kathleen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chou William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nichols Westontrack record | Buy | $2.3K | conv 32 | SEC |
| Nichols Westontrack record | Buy | $83.2K | conv 30 | SEC |
| Nichols Westontrack record | Buy | $138.3K | conv 30 | SEC |
| Lynx1 Capital Management LPtrack record | Buy | $71.4K | conv 32 | SEC |
| Lynx1 Capital Management LPtrack record | Buy | $283K | conv 32 | SEC |
| Lynx1 Capital Management LPtrack record | Buy | $379.3K | conv 33 | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $81.1K | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $45.8K | SEC |